HEALTH● LOWAug 12 · Aug 12, 2026, 11:58 PM
Seastar medical targets NEUTRALIZE-AKI enrollment completion around year-end or Q1 2027 as QUELIMMUNE adoption reaches 20 hospitals
Seeking Alpha Tech
Seastar Medical aims to complete enrollment for its NEUTRALIZE-AKI study around year-end or Q1 2027, while its QUELIMMUNE product has been adopted by 20 hospitals.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH14m agoKenya records second Ebola case as outbreak in Congo keeps growingEuroNews [en]HEALTH24m agoI work in the NHS and Malawi – we need to urgently rethink how we see health spendingThe Independent WorldHEALTH1h agoVaccines, antibiotics: Africa's push for pharma independence [Business Africa]Africanews [en]HEALTH1h agoNumber of people receiving weight loss jabs on NHS in Scotland revealedthenational.scot · United Kingdom